Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Prospects for an SV40 vaccine
Autore:
Imperiale, MJ; Pass, HI; Sanda, MG;
Indirizzi:
Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA Univ Michigan Ann Arbor MI USA 48109 l & Immunol, Ann Arbor, MI 48109 USA Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA Univ Michigan Ann Arbor MI USA 48109 rehens Canc, Ann Arbor, MI 48109 USA Univ Michigan, Sch Med, Ctr Gene Therapy, Ann Arbor, MI 48109 USA Univ Michigan Ann Arbor MI USA 48109 ene Therapy, Ann Arbor, MI 48109 USA Univ Michigan, Sch Med, Dept Surg, Ann Arbor, MI 48109 USA Univ Michigan Ann Arbor MI USA 48109 , Dept Surg, Ann Arbor, MI 48109 USA Wayne State Univ, Karmanos Canc Ctr, Sch Med, Detroit, MI 48202 USA Wayne State Univ Detroit MI USA 48202 Ctr, Sch Med, Detroit, MI 48202 USA
Titolo Testata:
SEMINARS IN CANCER BIOLOGY
fascicolo: 1, volume: 11, anno: 2001,
pagine: 81 - 85
SICI:
1044-579X(200102)11:1<81:PFASV>2.0.ZU;2-T
Fonte:
ISI
Lingua:
ENG
Soggetto:
MALIGNANT PLEURAL MESOTHELIOMA; LARGE TUMOR-ANTIGEN; PHASE-I TRIAL; CARCINOEMBRYONIC ANTIGEN; SV40-TRANSFORMED CELLS; PROSTATE-CANCER; LYMPHOCYTES-T; CEA VACCINE; IMMUNITY; VIRUS;
Keywords:
SV40; vaccine; T antigen; vaccinia virus; gene therapy;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
39
Recensione:
Indirizzi per estratti:
Indirizzo: Imperiale, MJ Univ Michigan, Sch Med, Dept Microbiol & Immunol, 1500 E MedCtr Dr,6310 Canc Ctr, Ann Arbor, MI 48109 USA Univ Michigan 1500 E Med CtrDr,6310 Canc Ctr Ann Arbor MI USA 48109
Citazione:
M.J. Imperiale et al., "Prospects for an SV40 vaccine", SEM CANC B, 11(1), 2001, pp. 81-85

Abstract

The identification of SV40 as a possible cause of human cancer leads to the question of whether the unique properties of the virus can be exploited to treat patients with SV40-positive mesotheliomas, which are otherwise refractory to successful intervention. A modified SV40 T antigen, from which the transforming domains have been removed, has been cloned into a vaccinia virus vector and tested in animal tumor model systems. It has been shown to be effective against both subsequent tumor challenge and pre-existing tumors. Thus, the potential exists for use of such a vaccine in mesothelioma patients.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 09/07/20 alle ore 20:51:19